Surrogate endpoints and competing risk of death in cardiac arrest research
- PMID: 27353499
- PMCID: PMC4926290
- DOI: 10.1186/s13054-016-1345-y
Surrogate endpoints and competing risk of death in cardiac arrest research
Abstract
We urgently need new therapies to improve outcomes after cardiac arrest. Initial studies typically target surrogate endpoints, and these studies help to inform subsequent larger trials that are powered to measure more patient-orientated clinical outcomes such as survival. The competing risk of death and premature assessment of neurological prognosis pose significant challenges to measuring these surrogate endpoints after cardiac arrest.
Comment on
-
Corticosteroid therapy in refractory shock following cardiac arrest: a randomized, double-blind, placebo-controlled, trial.Crit Care. 2016 Apr 3;20:82. doi: 10.1186/s13054-016-1257-x. Crit Care. 2016. PMID: 27038920 Free PMC article. Clinical Trial.
References
-
- Nolan JP, Neumar RW, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation. 2008;79(3):350–79. doi: 10.1016/j.resuscitation.2008.09.017. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
